Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Branching enzyme deficiency: expanding the clinical spectrum.
Paradas C, Akman HO, Ionete C, Lau H, Riskind PN, Jones DE, Smith TW, Hirano M, Dimauro S. Paradas C, et al. Among authors: riskind pn. JAMA Neurol. 2014 Jan;71(1):41-7. doi: 10.1001/jamaneurol.2013.4888. JAMA Neurol. 2014. PMID: 24248152 Free PMC article.
Relationships between multiple sclerosis and depression.
Byatt N, Rothschild AJ, Riskind P, Ionete C, Hunt AT. Byatt N, et al. J Neuropsychiatry Clin Neurosci. 2011 Spring;23(2):198-200. doi: 10.1176/jnp.23.2.jnp198. J Neuropsychiatry Clin Neurosci. 2011. PMID: 21677250
Vitamin D and multiple sclerosis.
Weinstock-Guttman B, Mehta BK, Ramanathan M, Karmon Y, Henson LJ, Halper J, Riskind P. Weinstock-Guttman B, et al. Neurologist. 2012 Jul;18(4):179-83. doi: 10.1097/NRL.0b013e31825bbf35. Neurologist. 2012. PMID: 22735240 Review.
gMS-Classifier1 does not predict disability progression in multiple sclerosis.
van Rossum JA, Killestein J, Villar LM, Riskind PN, Freedman MS, Teunissen C. van Rossum JA, et al. Among authors: riskind pn. Mult Scler. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. Mult Scler. 2019. PMID: 30168749 Free PMC article. No abstract available.
Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study.
Govindarajan KA, Datta S, Hasan KM, Choi S, Rahbar MH, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group. Govindarajan KA, et al. Hum Brain Mapp. 2015 Oct;36(10):3749-3760. doi: 10.1002/hbm.22875. Epub 2015 Jun 19. Hum Brain Mapp. 2015. PMID: 26096844 Free PMC article. Clinical Trial.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
22 results